Zanidatamab

Background: According to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to significant anti-tumo...

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1

Completed

Interventions: Biological: Zanidatamab
Drug: Docetaxel
Biological: Tislelizumab
Drug: Capecitabine
Drug: Oxaliplatin

Locations: 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Phase 3

Interventions: Drug: Tislelizumab
Drug: Pamiparib
Drug: Sitravatinib
Drug: BGB-15025
Drug: Zanidatamab
Drug: Temozolomide
Drug: Ociperlimab
Drug: BAT1706
Drug: Fruquintinib
Drug: BGB-A445
Drug: Surzebiclimab
Drug: Lenvatinib
Drug: LBL-007

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Standard Therapy
Drug: AMG 386 with or without Trastuzumab
Drug: AMG 479 (Ganitumab) plus Metformin
Drug: MK-2206 with or without Trastuzumab
Drug: T-DM1 and Pertuzumab
Drug: Pertuzumab and Trastuzumab
Drug: Ganetespib
Drug: ABT-888
Drug: Neratinib
Drug: PLX3397
Drug: Pembrolizumab - 4 cycle
Drug: Talazoparib plus Irinotecan
Drug: Patritumab and Trastuzumab
Drug: Pembrolizumab - 8 cycle
Drug: SGN-LIV1A
Drug: Durvalumab plus Olaparib
Drug: SD-101 + Pembrolizumab
Drug: Tucatinib plus trastuzumab and pertuzumab
Drug: Cemiplimab
Drug: Cemiplimab plus REGN3767
Drug: Trilaciclib with or without trastuzumab + pertuzumab
Drug: SYD985 ([vic-]trastuzumab duocarmazine)
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Drug: Dan222 + Niraparib
Drug: Sarilumab + Cemiplimab + Paclitaxel
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Drug: Amcenestrant
Drug: Amcenestrant + Abemaciclib
Drug: Amcenestrant + Letrozole
Drug: ARX788
Drug: ARX788 + Cemiplimab
Drug: VV1 + Cemiplimab
Drug: Datopotamab deruxtecan
Drug: Datopotamab deruxtecan + Durvalumab
Drug: Zanidatamab
Drug: Lasofoxifene
Drug: Z-endoxifen
Drug: ARV-471
Drug: ARV-471 + Letrozole
Drug: ARV-471 + Abemaciclib
Drug: Endoxifen + Abemaciclib
Drug: Rilvegostomig + TDXd
Drug: AMG 386 and Trastuzumab

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Kansas, Westwood, Kansas, United States

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.